Modification | Reference |
---|---|
Enhancing tumor tropism | |
 RGD modification | |
 5/3 chimerism | |
 Fully serotype 3, Ad3/Ad11p | |
Safety, restricting replication to cancer cells | |
 E1A gene 24-base pair deletion | |
 hTERT promoter | |
 p53 promoter | [69] |
 CEA promoter | [70] |
 PSA promoter | [71] |
 E2F promotor | [72] |
 Cox2l promoter | [73] |
Transgenes, enhancing efficacy | |
 Cytosine deaminase and thymidine kinase | [74] |
 Ganciclovir and/or 5-fluorocytosine (5-FC) prodrugs | [75] |
 GMCSF | |
 CD40L | |
 hNIS | [80] |
 TNFalpha and interleukin 2 | NCT04217473 |
 CD40L and 41BBL | NCT03225989 |
 PH20 hyaluronidase | NCT03284268 |
 Anti-CTLA4 | [81] |
 IL-12 and decorin | [82] |
 OX40L | [83] |
 EGFR | [84] |
 FR-a | [85] |
 FAP | [10] |
 CD44v6 | [86] |